- AutorIn
- Jan Gaertner Clinic for Palliative Care, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg
- Ulrike M. StamerDepartment of Anesthesiology and Pain Medicine, Inselspital, University of Bern
- Constanze RemiDepartment of Palliative Medicine, University Hospital Bonn
- Raymond Voltz
- Claudia Bausewein
- Rainer Sabatowski
- Stefan Wirz
- Gabriele Müller-Mundt
- Steffen T. Simon
- Anne Pralong
- Friedemann Nauck
- Markus Follmann
- Lukas Radbruch
- Winfried Meißner
- Titel
- Metamizole/dipyrone for the relief of cancer pain
- Untertitel
- A systematic review and evidence-based recommendations for clinical practice
- Zitierfähige Url:
- https://nbn-resolving.org/urn:nbn:de:bsz:14-qucosa2-353637
- Quellenangabe
- Palliative medicine Erscheinungsort: London
Verlag: Sage
Erscheinungsjahr: 2017
Jahrgang: 31
Heft: 1
Seiten: 26-34
E-ISSN: 1477-030X - Erstveröffentlichung
- 2017
- Abstract (EN)
- Background: Dipyrone (metamizole) is one of the most widely used non-opioid analgesics for the treatment of cancer pain. Aim: Because evidence-based recommendations are not yet available, a systematic review was conducted for the German Guideline Program in Oncology to provide recommendations for the use of dipyrone in cancer pain. Design: First, a systematic review for clinical trials assessing dipyrone in adult patients with cancer pain was conducted. Endpoints were pain intensity, opioid-sparing effects, safety, and quality of life. Data sources: The search was performed in MedLine, Embase (via Ovid), and the Cochrane Library (1948–2013) and additional hand search was conducted. Finally, recommendations were developed and agreed in a formal structured consensus process by 53 representatives of scientific medical societies and 49 experts. Results: Of 177 retrieved studies, 4 could be included (3 randomized controlled trials and 1 cohort study, n = 252 patients): dipyrone significantly decreased pain intensity compared to placebo, even if low doses (1.5–2 g/day) were used. Higher doses (3 × 2 g/day) were more effective than low doses (3 × 1 g/day), but equally effective as 60 mg oral morphine/day. Pain reduction of dipyrone and non-steroidal anti-inflammatory drugs did not differ significantly. Compared to placebo, non-steroidal anti-inflammatory drugs, and morphine, the incidence of adverse effects was not increased. Conclusion: Dipyrone can be recommended for the treatment of cancer pain as an alternative to other non-opioids either alone or in combination with opioids. It can be preferred over non-steroidal anti-inflammatory drugs due to the presumably favorable side effect profile in long-term use, but comparative studies are not available for long-term use.
- Andere Ausgabe
- Link zum Artikel, der zuerst in der Zeitschrift 'Palliative Medicine' erschienen ist.
DOI: 10.1177/0269216316655746 - Freie Schlagwörter (DE)
- Dipyron, Palliativmedizin, Neoplasmen, Schmerzbehandlung, Überprüfung, nichtsteroidale entzündungshemmende Mittel
- Freie Schlagwörter (EN)
- Dipyrone, palliative care, neoplasms, pain management, review, non-steroidal anti-inflammatory agents
- Klassifikation (DDC)
- 610
- Verlag
- Sage, London
- Version / Begutachtungsstatus
- publizierte Version / Verlagsversion
- URN Qucosa
- urn:nbn:de:bsz:14-qucosa2-353637
- Veröffentlichungsdatum Qucosa
- 04.11.2019
- Dokumenttyp
- Artikel
- Sprache des Dokumentes
- Englisch
- Lizenz / Rechtehinweis